Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 240Rectal Neoplasms 93Colonic Neoplasms 91Pancreatic Neoplasms 87Stomach Neoplasms 68Neoplasm Metastasis 47Esophageal Neoplasms 41Neoplasms 36Small Cell Lung Carcinoma 29Lung Neoplasms 29Neuroblastoma 28Glioblastoma 28Glioma 27Brain Neoplasms 26Carcinoma, Non-Small-Cell Lung 22Adenocarcinoma Of Esophagus 20Gliosarcoma 19Breast Neoplasms 18Astrocytoma 18Esophageal Squamous Cell Carcinoma 17Central Nervous System Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Oligodendroglioma 13Adenocarcinoma 13Rhabdomyosarcoma 10Gastrointestinal Neoplasms 10Biliary Tract Neoplasms 10Sarcoma 9Gallbladder Neoplasms 9Cholangiocarcinoma 9

Interventions

dehydroftorafur 2Taxes 2Radiotherapy 2Radiation 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2Platinum 1Nivolumab 1Gemcitabine 1Cisplatin 1Capecitabine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Adenocarcinoma × Irinotecan × Clear all
NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT03970252 2024-08-09

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
28 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡